Please assess the completion status of the following clinical trial:

Trial Title: The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* the presence of hepatitis B surface antigen (HBsAg) in the serum for at least 6 months.~* evidence of active viral replication as documented by measurable HBV DNA in the serum (≥2000IU/mL).~Exclusion Criteria:~* Less than 18 years old.~* history of ESKD or kidney transplantation.~* unknown baseline estimated glomerular filtration rate (eGFR).~* coexistence with other liver diseases such as alcoholic liver disease, autoimmune hepatitis, drug-induced liver injury, or other viral infections(hepatitis A, C, and E virus or HIV infection).~* concomitant with malignant tumor or other serious diseases affecting survival time.~* patients with missing data. follow-up period of \<48 weeks.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tenofovir alafenamide (Type: EXPERIMENTAL): tenofovir alafenamide,Gilead Sciences,capsule,25 mg,once a day,Continuous use for 48 weeks.
- entecavir (Type: EXPERIMENTAL): entecavir,Fujian cosunter pharmaceutical co.LTD,capsule,0.5mg,once a day,Continuous use for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).